A Study of Imvotamab in Severe Systemic Lupus Erythematosus
NCT06041568
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
17
Enrollment
INDUSTRY
Sponsor class
Stopped
Company Decision.
Conditions
Systemic Lupus Erythematosus
Lupus Erythematosus
Interventions
DRUG:
Imvotamab
Sponsor
IGM Biosciences, Inc.